



吉林大学  
JILIN UNIVERSITY

# Panacea: Enhancing Graph Learning with Multimodal Semantics for Drug Repositioning

**Zijun Dou**<sup>1</sup>, Yun Zhang, Baokun Zhang, Lingxiao Li,  
Xiaoyue Feng, Renchu Guan, Xiaosong Han

1. Presenter. Email: [douzijunabc@gmail.com](mailto:douzijunabc@gmail.com)


# Outline




Background



Design



Experiment



Conclusion


# Outline




Background



Design



Experiment



Conclusion

# Modern Drug Development




Modern drug development is a **multistage, high-risk process** of discovering and testing new molecules to achieve regulatory approval for therapeutic use

## The Problem



- **Time-Consuming:** 10-15 years
- **Costly:** Over \$2 billion
- **High Failure Rate:** Over 90%

# Drug Repositioning



## The Opportunity

- **A New Paradigm:** Drug Repositioning
- **Definition:** Identifying new therapeutic uses for existing, approved drugs ("old drugs, new tricks")
- **Key Advantages:**
  - **Reduced Time & Cost:** Bypasses early-stage discovery and pre-clinical testing
  - **Lower Risk:** Safety and pharmacokinetic profiles are already well-established


## The Role of AI

- Computational approaches are crucial for systematically and efficiently identifying high-potential drug repositioning candidates from vast biomedical data

# Problem Formulation


## Formulation as a Graph

- **Model:** A general biomedical graph
  - Nodes represent the core entities, such as drugs and diseases
  - Edges denote known drug-drug, drug-disease, and disease-disease interactions
- **Task:** Predicting potential new drug-disease associations
- Existing approaches mainly rely on **Graph Neural Networks (GNNs)** for representation learning




# Related Works

## Taxonomy of graph-based learning methods for drug repositioning



# Limitations



## ? Data Sparsity

- ① The scarcity of high-quality labeled drug-disease associations leads to weak input representations and undermines the foundation for effective graph learning


## ? Over-smoothing

- ① Multi-layer message passing in GNNs leads to indistinguishable node representations, severely degrading model performance and generalization.



# Our Goal

Our goal is to design an automated *multimodal semantics-enhanced* graph learning framework for drug repositioning



- **Collect multimodal biomedical data:** including drug, disease, and biomedical graphs
- **Encode modality-specific information:** generate unified embeddings for each modality
- **Perform graph learning:** capture structural and semantic relationships
- **Predict novel drug-disease associations:** enable automated drug repositioning

# Key Challenges

Limitation 1  
**Data sparsity**



## Challenge 1

**Multimodal semantic integration:** How to effectively integrate heterogeneous biomedical modalities, such as biomedical graphs, molecular structures, and textual symptoms descriptions


Limitation 2  
**Over-smoothing**



## Challenge 2

**Structural expressiveness under sparse inputs:** How to preserve representation diversity and maintain expressive power as the number of graph layers increase


# Outline




Background



Design




Experiment



Conclusion

# Model Overview



Panacea is an automated **multimodal** semantics-enhanced **graph learning** framework for **drug repositioning**. It mainly includes (a) Multimodal Semantic Modeling, (b) Hierarchical Graph Learning, and (c) Drug Repositioning


# Multimodal Semantic Modeling

## Modality Data

- Biomedical graphs (drug, disease)
- Drug SMILES strings from PubChem
- Disease symptom descriptions from OMIM

## Encoding

- Graph Edge  $\rightarrow$  Edge encoder  $\rightarrow$  Topology embedding
- SMILES  $\rightarrow$  MolBERT  $\rightarrow$  Structure-aware embedding
- Symptom Text  $\rightarrow$  ChatGPT-4o  $\rightarrow$  compress and standardize  $\rightarrow$  Qwen2.5-7B-Instruct  $\rightarrow$  Textual embedding



# Multimodal Semantic Modeling

## Prompt Case

- **Motivation:** Clinical symptom descriptions exhibit varying lengths and inconsistent quality
- **Example:** Overly long descriptions may contain redundant or irrelevant information
- **Method:** Leverage ChatGPT-4o to **compress and standardize** the symptom texts, ensuring semantic consistency and uniform length distribution

### Example

#### Input:

INHERITANCE - Autosomal recessive GROWTH Height - Short stature HEAD & NECK Head - Microcephaly - Brachycephaly - Turribrachycephaly - Plagiocephaly (in some patients) - Wide fontanelles Face – Craniofacial dysplasia - Prominent forehead - Midface hypoplasia - ‘Fishlike’ facies - Choanal atresia or choanal stenosis - Micrognathia - Prognathism (in some patients) Ears - Low-set ears - Dysplastic ears (in some patients) - Posteriorly rotated ears (in some patients) - Protruding ears (in some patients) - Hearing loss, mixed (in some patients) Eyes - Exophthalmos - Downslanting palpebral fissures - Hypertelorism (in some patients) - Arched eyebrows (in some patients) Nose - Hypoplastic nose - Depressed nasal bridge Mouth - Gingival hyperplasia - Cleft palate - High palate - Small mouth - Wide mouth (in some patients) - Large protruding tongue Teeth - Abnormal teeth (in some patients) - Natal teeth (in some patients) - Small teeth (in some patients) - Enamel dysplasia (in some patients)

#### Prompt:




Please rewrite the clinical symptom description into a concise and standardized format suitable for structured clinical NLP tasks. Focus on key abnormal findings, remove redundancies, and maintain medical accuracy.

#### Refinement:

**Autosomal recessive disorder** characterized by **short stature, craniofacial dysplasia, midface hypoplasia, microcephaly, low-set dysplastic ears, hearing loss, exophthalmos, cleft or high palate, wide fontanelles, and dental abnormalities.**

# Multimodal Semantic Modeling

## Distribution Experiment




- **Experiment result:** After refinement, clinical description lengths are shortened and standardized to a more uniform length

# Multimodal Semantic Modeling

## Alignment and Fusion


- **Motivation:** Enable effective alignment and produce modality-compatible representations
- Introduce a lightweight **linear projection layer**, mapping the drug molecular embeddings into the latent space of textual modality
  - $\mathbf{H}_q = \mathbf{W} \cdot \mathbf{Z}_q$
- Compute a **semantic-aware similarity**  $w_{ij}$  score using cosine similarity
- Obtain **adaptive edge embedding** by fusing structure- and semantics-aware components
  - $\mathbf{H}_w = \mathbf{Z}_w + \beta \cdot \mathbf{MLP}(w_{ij})$






# Hierarchical Graph Learning

- **Goal:** Captures higher-order dependencies and alleviates the over-smoothing problem
- **Method:** Employs a novel Graph Isomorphism Network with gated mechanisms and residual connections
- Builds **hierarchical receptive fields** across k-hop neighborhoods
- Progressively integrate structural signals from **near to distant** nodes, enhancing the representation capacity



# Hierarchical Graph Learning


## GIN Layer




- the message passing within each GIN layer proceeds in **three stages**
  - weighted neighborhood aggregation**, incorporating structure-aware and semantics-aware edge weights  $\rightarrow \mathbf{a}_i^{(l)} = \sum_{j \in \mathcal{N}(i)} \mathbf{H}_w^{ij} \odot \mathbf{h}_j^{(l-1)}$
  - adaptive gating mechanism**, control the integration of newly aggregated information and the original semantics  $\rightarrow \mathbf{g}_i^{(l)} = \sigma \left( \text{MLP} \left( \left[ \mathbf{a}_i^{(l)} \parallel \mathbf{h}_i^{(0)} \right] \right) \right)$ ,  $\mathbf{c}_i^{(l)} = \mathbf{c}_i^{(l-1)} + \mathbf{g}_i^{(l)}$
  - residual update**, compute the candidate representation  $\rightarrow \mathbf{h}_i^{(l)} = \text{MLP} \left( \mathbf{a}_i^{(l)} \right) + \left( 1 - \mathbf{c}_i^{(l)} \right) \odot \mathbf{h}_i^{(0)}$

# Downstream Task: Drug Repositioning

- **Input:** Final drug and disease embeddings
- **Scoring:**
  - Dot-product
    - $s_{ij} = \mathbf{H}_q^{i'} \cdot \mathbf{H}_p^{j'} = \sum_{k=1}^d (\mathbf{H}_q^{i'})_k \cdot (\mathbf{H}_p^{j'})_k$
  - Sigmoid
    - $y_{ij} = \sigma(s_{ij}) = \frac{1}{1 + \exp(-s_{ij})}$
  - association probability
- **Loss:** Composite loss which jointly optimizes multimodal semantic modeling and hierarchical graph learning




# Outline




Background



Design



Experiment



Conclusion

# Research Questions



## **RQ1: Effectiveness of Drug Repositioning**

Does Panacea achieve superior performance on drug repositioning compared to existing SOTA methods?



## **RQ2: Ablation Study**

How effective are Panacea's core design components?



## **RQ3: Multimodal Representation Analysis**

What does Panacea learn through multimodal graph representation learning?



## **RQ4: Over-smoothing Mitigation Verification**

Does Panacea effectively mitigate the over-smoothing issue commonly observed in graph learning?



## **RQ5: Hyperparameter Robustness Evaluation**

How do hyperparameter configuration affect the performance of Panacea?



## **RQ6: Case Study**

Can Panacea discover clinically relevant drug-disease associations supported by literature evidence?

# Experiment Settings

## Baselines

- Graph representation learning
  - DRHGCM, SCMFDD, SCPMF
- Graph propagation learning
  - HDGAT
- Graph heterogeneous learning
  - AutoDR, HNDR

## Datasets

Dataset	No.of drugs	No.of diseases	No.of associations	Sparsity
Fdataset [8]	593	313	1933	1.04%
Cdataset [9]	663	409	2352	0.87%
LRSSL [10]	763	681	3051	0.59%

## Metrics

- **AUROC, AUPRC**: assess the model's overall ranking performance
- **F1-score, Precision, Recall**: measure the prediction reliability at different decision thresholds
- For all metrics, higher values indicate better performance

# Results




## RQ1: Effectiveness of Drug Repositioning

Dataset	Metric	Model						Ours
		HDGAT	DRHGNCN	SCPMF	SCMFDD	HNRD	AutoDR	
Fdataset	F1-score	0.493 ± 0.004	0.516 ± 0.007	0.418 ± 0.006	0.364 ± 0.004	0.469 ± 0.008	0.502 ± 0.005	<b>0.518 ± 0.006</b>
	Precision	0.734 ± 0.006	0.690 ± 0.008	0.556 ± 0.008	0.515 ± 0.004	0.701 ± 0.008	0.667 ± 0.007	<b>0.788 ± 0.007</b>
	Recall	0.371 ± 0.006	<b>0.404 ± 0.006</b>	0.335 ± 0.007	0.282 ± 0.003	0.352 ± 0.011	0.402 ± 0.006	0.386 ± 0.006
	AUROC	0.911 ± 0.001	<b>0.944 ± 0.002</b>	0.893 ± 0.001	0.776 ± 0.001	0.881 ± 0.004	0.943 ± 0.002	0.943 ± 0.001
	AUPRC	0.303 ± 0.002	0.543 ± 0.006	0.349 ± 0.006	0.005 ± 0.000	0.350 ± 0.006	0.539 ± 0.008	<b>0.562 ± 0.005</b>
Cdataset	F1-score	0.572 ± 0.007	0.624 ± 0.006	0.551 ± 0.007	0.466 ± 0.003	0.557 ± 0.007	0.564 ± 0.005	<b>0.638 ± 0.006</b>
	Precision	0.634 ± 0.006	0.730 ± 0.007	0.572 ± 0.007	0.608 ± 0.005	0.597 ± 0.008	<b>0.803 ± 0.007</b>	0.726 ± 0.007
	Recall	0.521 ± 0.006	0.545 ± 0.007	0.531 ± 0.006	0.378 ± 0.004	0.521 ± 0.007	0.435 ± 0.005	<b>0.553 ± 0.006</b>
	AUROC	0.925 ± 0.002	0.960 ± 0.001	0.913 ± 0.002	0.793 ± 0.001	0.913 ± 0.002	0.916 ± 0.001	<b>0.963 ± 0.001</b>
	AUPRC	0.337 ± 0.002	<b>0.640 ± 0.005</b>	0.423 ± 0.004	0.005 ± 0.000	0.423 ± 0.004	0.625 ± 0.004	<b>0.640 ± 0.004</b>
LRSSL	F1-score	0.422 ± 0.015	0.450 ± 0.015	0.403 ± 0.017	0.286 ± 0.008	0.412 ± 0.020	0.451 ± 0.015	<b>0.456 ± 0.017</b>
	Precision	0.389 ± 0.012	0.410 ± 0.017	0.352 ± 0.017	0.251 ± 0.007	0.366 ± 0.018	0.402 ± 0.015	<b>0.426 ± 0.017</b>
	Recall	0.462 ± 0.009	0.497 ± 0.010	0.472 ± 0.007	0.332 ± 0.002	0.472 ± 0.009	<b>0.515 ± 0.010</b>	0.497 ± 0.007
	AUROC	0.928 ± 0.002	0.957 ± 0.001	0.895 ± 0.001	0.768 ± 0.001	0.849 ± 0.003	0.948 ± 0.002	<b>0.959 ± 0.001</b>
	AUPRC	0.359 ± 0.002	0.417 ± 0.005	0.271 ± 0.002	0.004 ± 0.000	0.428 ± 0.004	0.417 ± 0.003	<b>0.432 ± 0.002</b>
Average	F1-score	0.422	0.530	0.457	0.372	0.479	0.506	<b>0.537</b>
	Precision	0.389	0.610	0.493	0.458	0.554	0.624	<b>0.647</b>
	Recall	0.462	<b>0.482</b>	0.446	0.330	0.448	0.451	0.479
	AUROC	0.921	0.954	0.900	0.779	0.881	0.936	<b>0.955</b>
	AUPRC	0.333	0.533	0.348	0.005	0.400	0.527	<b>0.545</b>
1 <sup>st</sup> Count		0	4	0	0	0	2	15

**Finding:** Panacea achieves **the highest score** in all 15 dataset-metric combinations

# Results

## RQ2: Ablation Study





- **w/o HGL** → moderate overall drop (up to **-6.4% AUPRC**)
- **w/o MSM/ Refinement** → large impact (**~11%↓ F1**), proving multimodal priors are useful
- **w/o RC** → severe precision degradation on sparse datasets (**-18.3% F1**)

**Finding:** All modules contribute to performance. **MSM** and **RC** are most critical, reducing **AUROC** by up to **5.5%** and **F1** by **18.3%** when removed



# Results

## RQ3: Multimodal Representation Analysis




- Left: before hierarchical graph learning → **scattered & mixed embeddings**
- Right: after hierarchical graph learning → **clearer clustering and semantic separation**

**Finding:** Panacea transforms heterogenous multimodal inputs into **well-structured and semantically meaningful embeddings**, enabling more accurate drug-disease association modeling

# Results

## RQ4: Over-smoothing Mitigation Verification

Similarity  $\uparrow$   $\Rightarrow$  Over-smoothing  $\uparrow$




**Average cosine similarity** between node embeddings at adjacent hops (lower = less over-smoothing)


**Finding:** Panacea effectively **alleviates over-smoothing**, maintaining expressive node representations across deep layers

# Results

## RQ5: Hyperparameter Robustness Evaluation



(a) Embedding Size



(b) Adaptive Weight

**Finding:** Panacea remains stable across different **embedding sizes** and **adaptive weights**, demonstrating strong robustness to hyperparameter variations

# Results


## RQ6: Case Study

- **Goal:** Validate whether predicted drug-disease associations are clinically meaningful and supported by literature
- **Takeaway:** Predicted associations are **clinically relevant and literature-supported**, demonstrating the practical utility of Panacea in real-world drug repositioning

TABLE IV: Representative drug-disease predictions made by Panacea and supporting evidences from the literature.

Diseases	DrugBankIDs	Candidate Drugs	Evidences
BC	DB01229	Paclitaxel	[27]
AD	DB00747	Scopolamine	[28]
PD	DB00246	Ziprasidone	[29]
BC	DB00755	Tretinoin	[30]
PNE	DB00321	Amitriptyline	[31]


# Outline




Background



Design



Experiment



Conclusion

# Conclusion

- **Panacea Framework:** We propose Panacea, a *multimodal semantics-enhanced graph learning* framework for drug repositioning
- **Multimodal Integration:** Panacea integrates *biomedical graphs*, *drug molecular structures*, and *disease symptom descriptions*, aligned via modality-specific encoders and a learnable fusion layer
- **Hierarchical Graph Learning:** A *gated hierarchical GIN* with residual connections enhances representation capacity and mitigates over-smoothing
- **Performance Gains:** Panacea achieves state-of-the-art results across three benchmark datasets, with consistent improvements in *F1*, *AUROC*, and *AUPRC*, particularly under *high data sparsity*
- **Future Work:** We plan to explore *fine-grained semantic alignment* and extend Panacea to broader biomedical association prediction tasks



吉林大学  
JILIN UNIVERSITY

# Thank You!

## Q & A

Panacea: Enhancing Graph Learning with Multimodal Semantics for Drug Repositioning